Biomedical Engineering Reference
In-Depth Information
FIGURE 8.7
In.vitro.viability.of.(A).MCF-7.breast.cancer.cells.and.(B).SK-BR-3.breast.cancer.cells.treated.with.placebo.nano-
particles.(Blank-NP20.and.Blank-NP20-HER),.Taxotere,.and.docetaxel-loaded.nanoparticles.(NP20.and.NP20-
HER).at.25.µg/ml.docetaxel.concentration.after.24.h.(left.group),.48.h.(middle.group),.and.72.h.(right.group).
treatment,.respectively.(n.=.6)..(Reproduced.with.permission.from.Sun.et.al.,.
Nanomedicine
.4(4):.431-445,.2009.)
Figure 8.6.that.NP20-HER.demonstrated.much.higher.cellular.uptake.eficiency.for.both.
MCF-7.and.SK-BR-3.cells.than.NP20..For.example,.it.can.be.found.from.Figure 8.6A.that.
NP20-HER.achieved.1.36-,.1.33-,.1.31-,.and.1.28-fold.higher.cellular.uptake.eficiencies.than.
NP20.after.0.5,.1.0,.2,.and.4.h.incubation.with.SK-BR-3.cells,.respectively..It.can.be.seen.in.
Figure 8.7B,.instead,.that.NP20-HER.showed.1.21-,.1.17-,.1.15-,.and.1.17-fold.higher.cellular.
uptake.eficiencies.than.NP20.after.0.5,.1.0,.2,.and.4.h.incubation.with.MCF-7.cells,.respec-
tively..NP20-HER.thus.showed.1.12-,.1.34-,.1.14-,.and.1.09-fold.higher.targeting.effects.for.
SK-BR-3.cancer.cells.(of.high.HER.2.overexpression).than.for.MCF-7.breast.cancer.cells.(of.
moderate.HER2.overexpression).after.0.5,.1.0,.2,.and.4.h.cell.culture,.respectively.
It.can.be.seen.from.the.irst.group.in.Figure 8.6B.that.the.cellular.uptake.eficiencies.for.a.
30.min.incubation.of.naked.nanoparticles.and.trastuzumab-modiied.nanoparticles.are.38.6.
and.52.5%.for.SK-BR-3.cells,.respectively..This.demonstrates.that.in.such.a.short.incubation.
period,. the. uptake. of. trastuzumab-modiied. nanoparticles. was. enhanced. in. comparison.
with.the.cellular.uptake.of.the.naked.nanoparticles,.which.is.in.accordance.with.the.litera-
ture..Moreover,.it.is.straightforward.from.both.Figure 8.6A.and.B.that.the.cellular.uptake.
depends.on.the.incubation.time,.and.the.longer.the.incubation.time,.the.higher.the.cellular.
uptake.eficiency.achieved..Similar.trends.were.also.found.in.our.earlier.work,.where.trastu-
zumab.was.physically.attached.to.the.PLGA-MMT.NPs.for.targeted.delivery.of.paclitaxel.
8.6.2 In Vitro Cytotoxicity
Figure 8.7.shows.the.in.vitro.viability.of.(A).MCF-7.breast.cancer.cells.(of.moderate.HER2.
overexpression).and.(B).SK-BR-3.breast.cancer.cells.(of.high.HER2.overexpression).treated.
with. placebo. nanoparticles. with. (Blank-NP20-HER). and. without. (Blank-NP20). trastu-
zumab. conjugation,. Taxotere
®
,. and. docetaxel-loaded. PLA-TPGS/TPGS-COOH. nanopar-
ticles. of. 20%. TPGS-COOH. with. (NP20-HER). and. without. (NP20). 25. µg/ml. docetaxel.
concentration.after.24,.48,.and.72.h.treatment,.respectively.(n.=.6)..The.results.are.shown.in.
the.form.of.cell.viability..The.sum.of.viability.and.mortality.is.always.100%..The.reason.we.
